PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth

American Journal of Pathology

Volumn 174, Issue 5, 2009, Pages 1869-1879

  Blando, Jorge ^a   Portis, Melisa ^a   Benavides, Fernando ^a   Alexander, Angela ^a   Mills, Gordon ^b   Dave, Bhuvanesh ^a   Conti, Claudio J ^a   Kim, Jeri ^b   Walker, Cheryl Lyn ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; MESSENGER RNA; MICROSATELLITE DNA; PROTEIN KINASE; PROTEIN KINASE B; PTEN PROTEIN, MOUSE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEFICIENCY; HISTOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; DISEASE COURSE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; INCIDENCE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSATELLITE REPEATS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS;

EID: 65649118955     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080055     Document Type: Article

References (52)

1. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumour suppressor gene. MMAC1, at chromosome 10q233 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362
2. Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006, 6:184-192 (Pubitemid 43292562)
3. Sulis ML, Parsons R: PTEN: from pathology to biology. Trends Cell Biol 2003, 13:478-483 (Pubitemid 37289398)
4. Eng C: PTEN: one gene, many syndromes. Hum Mutat 2003, 22:183-198 (Pubitemid 37071635)
5. Altomare DA, Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464 (Pubitemid 41637985)
6. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005, 8:179-183 (Pubitemid 41317589)
7. Shaw RJ, Cantley LC: Ras. PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430
8. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501 (Pubitemid 37328931)
9. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24 (Pubitemid 40070934)
10. Manning BD, Cantley LC: Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003, 28:573-576 (Pubitemid 38352801)
11. Li Y, Corradetti MN, Inoki K, Guan KL: TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004, 29:32-38 (Pubitemid 38068478)
12. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL: Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006, 173:279-289
13. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998, 95:5246-5250 (Pubitemid 28208583)
14. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995, 55:4800-4803
15. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57:4997-5000 (Pubitemid 27498107)
16. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998, 58:204-209 (Pubitemid 28047054)
17. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245 (Pubitemid 29190320)
18. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390
19. Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes Dev 2000, 14:2410-2434
20. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96:1563-1568 (Pubitemid 29098491)
21. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348-355 (Pubitemid 28357906)
22. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000, 60:3605-3611 (Pubitemid 30482183)
23. Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J, Groszer M, Martinez-Diaz H, Rozengurt N, Thomas G, Liu X, Wu H: Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 2006, 66:6492-6496 (Pubitemid 44085602)
24. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L, Suzuki A, Tsao MS, Chapman WB, Stambolic V, Mak TW: Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 2004, 101:1725-1730 (Pubitemid 38234221)
25. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP: Pten dose dictates cancer progression in the prostate. PLoS Biol 2003, 1:E59 (Pubitemid 39112137)
26. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H: Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221 (Pubitemid 37163835)
27. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J: Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 2005, 65:5730-5739 (Pubitemid 40911176)
28. Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D: Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 2008, 105:2521-2526
29. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP: Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001, 27:222-224 (Pubitemid 32157454)
30. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C: Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002, 99:2884-2889 (Pubitemid 34240555)
31. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM: Nkx3.1;Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003, 63:3886-3890 (Pubitemid 36917899)
32. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M: Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001, 98:11563-11568 (Pubitemid 32928768)
33. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730 (Pubitemid 41117277)
34. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP: Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008, 22:2172-2177
35. Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR: Lkb1 deficiency causes prostate neoplasia in the mouse. Cancer Res 2008, 68:2223-2232
36. Gomez MR, Sampson JR, Whittemore VH: Tuberous Sclerosis Complex. Edited by Harris JC. Oxford, Oxford University Press, 1999, pp 3-46
37. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T: Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999, 59:1206-1211 (Pubitemid 29136248)
38. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ: Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999, 104:687-695 (Pubitemid 29536354)
39. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP: Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 2005, 19:1779-1786 (Pubitemid 41126917)
40. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC: Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 2005, 19:1773-1778 (Pubitemid 41126916)
41. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD: Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004, 64:2270-2305
42. Maxwell P, McCluggage WG: Audit and internal quality control in immunohistochemistry. J Clin Pathol 2000, 53:929-932
43. Adams EJ, Green JA, Clark AH, Youngson JH: Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999, 52:75-77 (Pubitemid 29023513)
44. Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P: Coop- eration between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 2006, 66:2188-2194 (Pubitemid 43294929)
45. Wu L, Birle DC, Tannock IF: Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005, 65:2825-2831 (Pubitemid 40490085)
46. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62:6141-6145 (Pubitemid 35244463)
47. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004, 10:594-601 (Pubitemid 38796850)
48. Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB: Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004, 11: 225-254 (Pubitemid 38832827)
49. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ: Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome, Am J Pathol 2000, 157:2151-2159
50. Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS: Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol 2007, 8:R117
51. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, Cunha GR, Cardiff RD, Shen MM, Abate-Shen C: Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002, 62:2999-3004 (Pubitemid 34602384)
52. Xu Q, Majumder PK, Ross K, Shim Y, Golub TR, Loda M, Sellers WR: Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci USA 2007, 104:17771-17776 (Pubitemid 350210910)